Sun Pharmaceutical Industries Ltd

Showing SUNPHARMA
Past performance
Performance overview
Sun Pharmaceutical Industries Ltd
About Sun Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Limited is the fourth largest global specialty generic company, and the largest Indian pharmaceutical firm in the US, ranked No. 1 in India and No. 8 in the US. It offers a diverse product range, including generics, branded generics, and complex technology-intensive products, covering a wide array of therapeutic segments such as cardiology, neurology, dermatology, and oncology. With 43 manufacturing facilities worldwide, India and the US contribute to nearly 70% of its revenue, and it maintains a strong presence in Europe and emerging markets. Founded in 1983, Sun Pharma has expanded through strategic acquisitions and partnerships, such as the merger with Ranbaxy Laboratories and collaborations with companies like MSD and AstraZeneca. The company invests significantly in R&D, focusing on developing differentiated products, and has a robust pipeline in various therapeutic areas. Recent initiatives include launching innovative products like ILUMYA for psoriasis and expanding its global footprint with acquisitions like Concert Pharmaceuticals to enhance its specialty product portfolio.
Website sunpharma.com
Founded 1993
Headquarters Vadodara